NCT07435987Recruiting
Clinical Feasibility of the ARCHITECT Applicator in Cervical Cancer Brachytherapy
Clinical Feasibility of the ARCHITECT Applicator in High-dose-rate Cervical Cancer Brachytherapy
Source: ClinicalTrials.gov · Last updated 25 Sept 2026
Brief summary (registry, in English)
This prospective, non-randomised, single centre, phase I trial assesses the clinical feasibility of the use of the patient-tailored ARCHITECT applicator in locally advanced cervical cancer brachytherapy.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 25 (estimated)
- First submitted
- 29 Jan 2026
- Start date
- 22 Jul 2026
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- Erasmus Medical Center
- Diseases
- Cervical cancer
- NCT number
- NCT07435987
What you commit to
- Study type: Interventional
- Planned participants: 25
- From 22 Jul 2026 to the primary completion date, 31 Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Known nylon allergy.
Other
- Unable to give informed consent;
- Tumour extension in the lower 2/3rd of the vagina;
- Requiring a Geneva tandem with ovoids' size 13 mm in the first application for brachytherapy;
Who the study is looking for
- Locally advanced cervical cancer (FIGO 2018 stage 1B3-IVA) with indication for primary radiotherapy including brachytherapy
- Written informed consent
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Erasmus Medical Center Coordinator of this site? Confirm its status | Rotterdam | Netherlands | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.